UK Invests Additional $103 Million in COVID-19 Vaccine Research

Corona Virus

According to global media reports, a trial of the vaccine in rhesus macaque monkeys did not stop the animals from catching the virus and has raised questions about the vaccine's likely human efficacy and ongoing development. Even as researchers advance the programs through the development process, teams are also working through manufacturing concerns to deliver doses quickly if the candidates show efficacy.

"I recognise what we are now asking is more complex than simply staying at home - but this is a complex problem and we need to trust in the good sense of the British people".

As the effects of coronavirus intensify, countries all over the world have started to implement measures to develop a vaccine that could minimize the loss arising from this crisis.

Choreography Matthew Bourne echoed such opinions: "Lots of positivity in the news this morning about "UK going back to work" but until we can rehearse and play to packed theatres when can dance and theatre realistically think of returning to work without a vaccine or something similar?"

A team at the University of Oxford says they can have a million doses of a COVID-19 vaccine ready by September.

A recent non-peer-reviewed study published on May 13, 2020, showed that a single vaccination in rhesus macaques with ChAdOx1 nCoV-19 is effective in preventing damage to the lungs upon high dose challenge with SARS-CoV-2. Upon an encounter with the actual novel coronavirus, the body would already have the means to block that protein from binding to human cells.

The new funding took government funding of vaccine development to $460 million, said Mr Sharma.

Britain's Business Secretary Alok Sharma told reporters on Sunday that plans are in place to roll out the COVID-19 vaccine to 30 million people by September, Sky News reports.

In today's daily public briefing, Sharma praised the work at both Oxford University and Imperial College London, and said that the search for a vaccine to the virus is progressing well.

The scientists located a solitary dosage of the vaccine stopped all 6 immunized apes from creating pneumonia, however did not avoid infection outright.

He also added that AstraZeneca had finalized a "global licensing agreement" with Oxford University with government support.

If the Oxford vaccine is successful, AstraZeneca will work to make up to 30 million doses available by September for people in the United Kingdom, as part of an agreement to deliver 100 million doses in total.

The global death toll from the novel coronavirus has exceeded 314,000, with almost 4.7 million confirmed cases and over 1.72 million recoveries, according to a running tally by US-based Johns Hopkins University.

The wave of government spending on vaccines comes as local media reported on Sunday that Johnson told his Conservative Party colleagues he aims to return the country to near-normality by July. That's why it's necessary to continue looking for other therapies. The first tranche of volunteers have received the Oxford vaccine, with Imperial due to start clinical trials by mid-June.



Other news